seed
Stage
1
Investors
About
Exogenus Therapeutics develops exosome-based therapeutics derived from umbilical cord blood cells, targeting tissue regeneration and inflammatory diseases through their lead candidate Exo-101, which has demonstrated regenerative and immunomodulatory properties in preclinical studies.
Explore Exogenus Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.